Bioventus (BVS) Stock Price, News & Analysis

Company Overview

Bioventus Inc., a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain. Its surgical solutions comprise bone graft substitutes that increase bone formation to stimulate bone healing in spinal fusions and other orthopedic surgeries; and ultrasonic products used for precise bone cutting and sculpting, soft tissue management, and tissue debridement, in various surgeries, including minimally invasive applications. The company's product include, Osteoamp, an allograft-derived bone graft for bone grafting procedures; Exponent matrix for posterolateral spine procedures; Purebone for bone grafting procedures; Signafuse bone graft; Interfuse bone graft; Osteomatrix+ synthetic bone graft; Extractor for autologous cell and bone marrow extraction; reficio bone matrix; nexus ultrasonic surgical system; bonescalpel surgical solution; SonaStar for surgical procedures; and SonicOne ultrasonic cleansing and debridement system. The company's restorative therapies include a bone stimulation system and devices to help patients regain leg or hand function due to stroke, multiple sclerosis, or other central nervous system disorders. Its products include exogen, a bone healing system; L300 GO, a foot drop system; H200 rehabilitation system; Vector, a body weight support system; and Bioness integrated therapy system. It developing Talisman pulse generator and receiver for peripheral nerve stimulation. The company was founded in 2011 and is headquartered in Durham, North Carolina.

Key Stats

• Today's Range: $10.92 to $11.75
• 50-Day Range: $10.91 to $13.71
• 52-Week Range: $3.67 to $14.38
• Volume: 274,868 shs
• Average Volume: 496,783 shs
• Market Capitalization: $925.92 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $13.00
• Consensus Rating: Buy

Bioventus Stock Analysis - MarketRank™

Bioventus scored higher than 54% of companies evaluated by MarketBeat, and ranked 549th out of 963 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.5 / 5
• Analyst Rating: Buy

Consensus Rating

Bioventus has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Bioventus has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 17.07%

Earnings Growth

Earnings for Bioventus are expected to grow by 17.07% in the coming year, from $0.41 to $0.48 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Bioventus is -18.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Bioventus is -18.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Bioventus has a P/B Ratio of 4.08. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for BVS.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Bioventus does not currently pay a dividend.

Dividend Growth

Bioventus does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for BVS.

News and Social Media

• Score: 2.3 / 5
• News Sentiment: N/A

News Sentiment

Bioventus has a news sentiment score of 1.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.45 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Bioventus this week, compared to 2 articles on an average week.

Search Interest

Only 9 people have searched for BVS on MarketBeat in the last 30 days. This is a decrease of -10% compared to the previous 30 days.

MarketBeat Follows

Only 2 people have added Bioventus to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Bioventus insiders have not sold or bought any company stock.

Percentage Held by Insiders

32.90% of the stock of Bioventus is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

62.94% of the stock of Bioventus is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

BVS Stock Analysis - Frequently Asked Questions

How have BVS shares performed this year?

Bioventus' stock was trading at $5.27 at the start of the year. Since then, BVS shares have increased by 116.5% and is now trading at $11.41.
View the best growth stocks for 2024 here.

How were Bioventus' earnings last quarter?

Bioventus Inc. (NYSE:BVS) issued its quarterly earnings data on Tuesday, November, 5th. The company reported $0.06 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.06. The business had revenue of $138.96 million for the quarter, compared to the consensus estimate of $132.57 million. Bioventus had a negative net margin of 7.11% and a positive trailing twelve-month return on equity of 15.61%.

When did Bioventus IPO?

Bioventus (BVS) raised $126 million in an IPO on Thursday, February 11th 2021. The company issued 7,400,000 shares at $16.00-$18.00 per share. Morgan Stanley, J.P. Morgan, Goldman Sachs and Canaccord Genuity acted as the underwriters for the IPO.

Who are Bioventus' major shareholders?

Top institutional shareholders of Bioventus include Geode Capital Management LLC (1.16%), Royce & Associates LP (0.86%), State Street Corp (0.84%) and Charles Schwab Investment Management Inc. (0.48%). Insiders that own company stock include John A Bartholdson, Juniper Investment Company, Ll, William A Hawkins, Anthony P Bihl III, Anthony D'adamio, John Nosenzo, Mark Leonard Singleton, Kenneth Michael Reali and Katrina J Church.
View institutional ownership trends.

How do I buy shares of Bioventus?

Shares of BVS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Bioventus own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Bioventus investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), ServiceNow (NOW), Adobe (ADBE) and Arista Networks (ANET).

Company Calendar

• Last Earnings: 11/05/2024
• Today: 11/20/2024
• Fiscal Year End: 12/31/2024
• Next Earnings (Estimated): 3/11/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Surgical & medical instruments
• Sub-Industry: Medical Equipment
• Current Symbol: NYSE:BVS
• CUSIP: N/A
• CIK: 1665988
• Web: www.bioventus.com
• Phone: 919-474-6700
• Fax: N/A
• Employees: 1,200
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $13.00
• High Stock Price Target: $17.00
• Low Stock Price Target: $7.00
• Potential Upside/Downside: +13.9%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.61)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 27.83
• P/E Growth: N/A
• Net Income: $-156,230,000.00
• Net Margins: -7.11%
• Pretax Margin: -10.41%
• Return on Equity: 15.61%
• Return on Assets: 4.01%

Debt

• Debt-to-Equity Ratio: 1.85
• Current Ratio: 1.41
• Quick Ratio: 0.99

Sales & Book Value

• Annual Sales: $555.06 million
• Price / Sales: 1.67
• Cash Flow: $0.80 per share
• Price / Cash Flow: 14.21
• Book Value: $2.80 per share
• Price / Book: 4.08

Miscellaneous

• Outstanding Shares: 81,155,000
• Free Float: 54,455,000
• Market Cap: $925.98 million
• Optionable: Not Optionable
• Beta: 0.88